Can patients remain on clopidogrel (Effient) for more than one year?

Can You Keep People on Effient Over 1 Year?

Yes, continuation of prasugrel (Effient) beyond 12 months may be considered in patients after drug-eluting stent (DES) placement, though this is a Class IIb recommendation with Level of Evidence C, meaning it's based on weaker evidence and expert opinion. 1

Standard Duration Recommendations

The foundational guidance is clear for the first year:

• For ACS patients with stent placement: P2Y12 inhibitor therapy (including prasugrel 10 mg daily) should be given for at least 12 months 1, 2
• This applies to both bare-metal stents (BMS) and drug-eluting stents (DES) 1
• Aspirin should be continued indefinitely at 81 mg daily 2

Beyond 12 Months: The Evidence

Continuation beyond 1 year is discretionary, not mandatory. The 2011 ACC/AHA/SCAI guideline specifically states: "Continuation of clopidogrel, prasugrel or ticagrelor beyond 12 months may be considered in patients undergoing placement of DES" 1. This was updated in 2016 to clarify that for ACS patients after coronary stent implantation who have tolerated DAPT without bleeding complications and are not at high bleeding risk, continuation beyond 12 months "may be reasonable" 2.

Key Considerations for Extended Therapy:

Patient Selection Criteria:

• Must have tolerated DAPT without bleeding complications in the first year
• Not at high bleeding risk (no prior bleeding on DAPT, no coagulopathy, not on oral anticoagulants) 2
• Increased risk of stent thrombosis may favor extended therapy 3

Important Caveats:

1. Bleeding Risk: The FDA label for Effient notes that in the TRITON-TIMI 38 trial, patients were treated for a median of 14.5 months, with 4,136 patients treated for more than 1 year 4. However, bleeding rates were consistently higher with prasugrel than clopidogrel throughout the study period.

2. High-Risk Populations: Prasugrel should be avoided in patients with 5:

   • History of stroke or TIA (Class III recommendation)
   • Age ≥75 years
   • Weight <60 kg
   • Likely need for urgent CABG

3. Risk-Benefit Balance: If the risk of morbidity from bleeding outweighs the anticipated benefit, earlier discontinuation is reasonable 1

Practical Algorithm for Decision-Making

At 12 months post-PCI, assess:

1. Bleeding history: Any bleeding events on DAPT? If yes → discontinue P2Y12 inhibitor
2. Bleeding risk factors: Age ≥75, weight <60 kg, history of stroke/TIA, need for anticoagulation? If yes → discontinue prasugrel
3. Ischemic risk: High-risk features like diabetes, prior MI, complex lesions, multiple stents? If yes → consider continuation
4. Adherence and tolerance: Has patient tolerated therapy well? If no → discontinue

If continuing beyond 12 months:

• Continue aspirin 81 mg daily indefinitely
• Continue prasugrel 10 mg daily (or 5 mg if weight <60 kg, though this population should generally avoid prasugrel)
• Reassess every 6-12 months for bleeding events or changing risk profile
• Avoid lapses in therapy, as discontinuation increases risk of stent thrombosis, MI, and death 4

Common Pitfalls

• Don't confuse Effient (prasugrel) with Plavix (clopidogrel): The question asks about Effient specifically, which has more limited data for extended use compared to clopidogrel
• Don't continue in high-risk bleeding patients: The modest ischemic benefit is offset by bleeding risk in vulnerable populations
• Don't stop abruptly without discussion: Premature discontinuation significantly increases thrombotic risk 4

The decision to extend prasugrel beyond 12 months should be individualized based on the balance between residual ischemic risk and bleeding risk, with careful attention to the specific contraindications for prasugrel use.